WINTON GROUP Ltd increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 36.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,666 shares of the medical research company’s stock after buying an additional 10,312 shares during the quarter. WINTON GROUP Ltd’s holdings in Thermo Fisher Scientific were worth $9,438,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Buckingham Asset Management LLC grew its position in Thermo Fisher Scientific by 104.2% during the third quarter. Buckingham Asset Management LLC now owns 2,608 shares of the medical research company’s stock worth $637,000 after buying an additional 1,331 shares in the last quarter. Gamco Investors INC. ET AL grew its position in Thermo Fisher Scientific by 4.3% during the third quarter. Gamco Investors INC. ET AL now owns 46,179 shares of the medical research company’s stock worth $11,271,000 after buying an additional 1,883 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Thermo Fisher Scientific by 6.4% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 18,182 shares of the medical research company’s stock worth $4,438,000 after buying an additional 1,089 shares in the last quarter. Zions Bancorporation acquired a new stake in Thermo Fisher Scientific during the third quarter worth approximately $915,000. Finally, Rockefeller Capital Management L.P. boosted its holdings in shares of Thermo Fisher Scientific by 6.6% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 21,066 shares of the medical research company’s stock valued at $5,141,000 after purchasing an additional 1,296 shares in the last quarter. 85.22% of the stock is currently owned by institutional investors and hedge funds.

In other news, CEO Marc N. Casper sold 125,520 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $247.50, for a total value of $31,066,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.49% of the stock is currently owned by corporate insiders.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $259.00 target price on the stock in a report on Monday, July 30th. Leerink Swann raised their target price on Thermo Fisher Scientific from $239.00 to $255.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Cleveland Research downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Thursday, October 18th. Morgan Stanley raised their target price on Thermo Fisher Scientific from $254.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday, October 25th. Finally, Robert W. Baird raised their target price on Thermo Fisher Scientific from $256.00 to $264.00 and gave the company an “outperform” rating in a report on Thursday, October 25th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $261.45.

Shares of TMO stock opened at $243.45 on Friday. The firm has a market capitalization of $98.84 billion, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 1.78 and a beta of 1.08. Thermo Fisher Scientific Inc. has a fifty-two week low of $181.51 and a fifty-two week high of $249.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.27 and a current ratio of 1.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 EPS for the quarter, beating the Zacks’ consensus estimate of $2.55 by $0.07. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The company had revenue of $5.92 billion during the quarter, compared to analysts’ expectations of $5.70 billion. During the same period in the prior year, the company earned $2.31 EPS. Thermo Fisher Scientific’s revenue was up 15.7% compared to the same quarter last year. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 11.04 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, September 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 15th. Stockholders of record on Monday, December 17th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Friday, December 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://theolympiareport.com/2018/11/10/winton-group-ltd-has-9-44-million-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.